查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球性傳播疾病檢測市場（2019-2029）：規模、份額、趨勢分析、機會、預測——按疾病、地點、設備、地區分類
市場調查報告書
商品編碼
1186467

全球性傳播疾病檢測市場（2019-2029）：規模、份額、趨勢分析、機會、預測——按疾病、地點、設備、地區分類

Sexually Transmitted Disease Testing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Disease ; By Location ; By Device ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 200 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球性傳播疾病檢測市場規模預計到 2022 年將達到 914 億美元，在 2023-2029 年的預測期內以 6.2% 的複合年增長率增長，到 2029 年將達到 1355 億美元。 推動市場的關鍵因素包括 STD 患病率和發病率的增加、國家篩查計劃的增加以及對全球 STD 檢測報銷的支持增加。 然而，與就診 STD 專科診所的患者相關的社會恥辱感以及對偏遠地區 STD 感染患者的強有力保護預計將阻礙分析期間的市場增長。

本報告研究了全球性病檢測市場，提供了市場概況、市場驅動因素和限制因素分析、市場機會、細分市場分析、競爭格局、COVID-19 它提供了系統信息，包括 19 種影響、概況重點公司等。

內容

第一章研究框架

第 2 章執行摘要

第 3 章全球性病檢測市場：洞察

  • 行業價值鏈分析
  • DROC 分析
    • 增長動力
      • 全球範圍內性傳播疾病的高流行率和發病率不斷上升
      • 實施國家篩查計劃
      • 支持 STD 檢測報銷
    • 約束因素
      • 與就診 STD 診所的患者相關的社會污名化
      • 為偏遠地區的性病感染者提供強有力的保護
    • 機會
      • 減少去政府診所的次數
      • 世界各地的國家篩選計劃
      • 新興經濟體中技術和 POC 測試提供商的利基機會
    • 任務
      • 嚴格監管
  • 技術進步/最新發展
  • 監管框架
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭激烈程度

第 4 章。全球性病檢測市場：概述

  • 市場規模和預測（2019-2029 年）
    • 按金額
  • 市場份額和預測
    • 按疾病分類
      • 衣原體
      • 梅毒
      • 淋病
      • 超單純形病毒
      • 人類免疫缺陷病毒
      • 硬下疳
      • 其他
    • 按位置
      • 實驗室
      • 護理點 (POC)
    • 按設備
      • 實驗設備
      • 護理點 (POC) 設備
    • 按地區
      • 北美
      • 歐洲
      • 亞太地區
      • 拉丁美洲
      • 中東和非洲

第五章北美性病檢測市場

  • 市場規模和預測（2019-2029 年）
    • 按金額
  • 市場份額和預測
    • 按疾病分類
    • 按位置
    • 按設備
    • 按國家
      • 美國
      • 加拿大

第 6 章歐洲性病檢測市場

  • 市場規模和預測（2019-2029 年）
    • 按金額
  • 市場份額和預測
    • 按疾病分類
    • 按位置
    • 按設備
    • 按國家
      • 德國
      • 英國
      • 意大利
      • 法國
      • 西班牙
      • 荷蘭
      • 其他歐洲

第 7 章亞太地區性病檢測市場

  • 市場規模和預測（2019-2029 年）
    • 按金額
  • 市場份額和預測
    • 按疾病分類
    • 按位置
    • 按設備
    • 按國家
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳大利亞和新西蘭
      • 印度尼西亞
      • 馬來西亞
      • 新加坡
      • 菲律賓
      • 越南
      • 亞太其他地區

第 8 章拉丁美洲的性病檢測市場

  • 市場規模和預測（2019-2029 年）
    • 按金額
  • 市場份額和預測
    • 按疾病分類
    • 按位置
    • 按設備
    • 按國家
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 哥倫比亞
      • 其他拉丁美洲

第 9 章中東和非洲的性傳播疾病檢測市場

  • 市場規模和預測（2019-2029 年）
    • 按金額
  • 市場份額和預測
    • 按疾病分類
    • 按位置
    • 按設備
    • 按國家
      • 沙特阿拉伯
      • 阿拉伯聯合酋長國
      • 卡塔爾
      • 科威特
      • 南非
      • 尼日利亞
      • 阿爾及利亞
      • 其他中東和非洲地區

第10章競爭格局

  • 主要公司及其產品列表
  • 全球性病檢測公司的市場份額分析（2022 年）
  • 按運營參數進行競爭性基準測試
  • 重大戰略發展（合併、收購、合作等）

第 11 章全球性病檢測市場：COVID-19 的影響

第12章公司概況（公司概況、財務矩陣、競爭格局、關鍵人才、主要競爭對手、聯繫人、戰略展望、SWOT分析）

  • Abbott Laboratories
  • BioMerieux, Inc.
  • Becton Dickinson Company
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Hologic, Inc.
  • Diasorin Molecular LLC
  • Roche Holding AG
  • Orasure Technologies, Inc.,
  • Thermo Fisher Scientific Inc.
  • AccuBioTech Co. Ltd.
  • AdvaCare Pharma
  • BIOGENIX Inc. Pvt. Ltd.
  • CTK Biotech Inc.
  • Everlywell Inc.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • 其他有影響力的公司

第 13 章關鍵戰略建議

第 14 章研究方法論

簡介目錄
Product Code: BWC23024

Global Sexually Transmitted Disease Testing Market Size Expands to Cross USD 135.5 Billion by 2029.

Global sexually transmitted disease (STD) testing market is flourishing because of an increasing prevalence and rising incidences of STDs, growing establishment of national screening programs, and rising support for STD testing reimbursements across the globe.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global sexually transmitted disease (STD) testing market size at USD 91.4 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global sexually transmitted disease testing market size to grow at a steady CAGR of 6.2% reaching a value of USD 135.5 billion by 2029. Major factors for the expansion of global sexually transmitted disease testing market include increasing public awareness and patient education, global rise in the incidence of sexually transmitted illnesses, increasing patient awareness through education campaigns, and a surge in government activities. The prevalence and incidence of sexually transmitted illnesses have increased significantly during the previous decade. As the frequency of sexually transmitted illnesses increases, countries worldwide are focused on the deployment of national screening programs to expand the coverage of sexually transmitted disease diagnosis. Also, the payment regulations for services related to sexually transmitted diseases have been favorable. Technology advancements and developments in the diagnosis of STDs are also projected to boost market expansion. Increased national screening program implementation to increase sexually transmitted disease diagnosis coverage will also boost the demand for STDs testing. These reasons are considerably driving the growth of the global sexually transmitted diseases testing market. However, social stigma associated with patients visiting specialized STD clinics and huge protection of patients infected with STDs in remotes areas are anticipated to hinder the market growth during the period in analysis.

Global Sexually Transmitted Disease Testing Market - Overview

Sexual health testing is a collection of diverse tests and procedures used to diagnose and detect sexually transmitted illnesses, such as Chlamydia, Gonorrhea, Trichomonas, HIV, HSV, HCV, HPV, and others. For sexual health testing, four major types of testing are employed, including Culture/Isolation of Organisms, Molecular Test, Immunology Assay, and others. HIV can be diagnosed using one of three HIV tests: antibody testing, antigen/antibody tests, and nucleic acid tests (NAT). STD prevalence and incidence have risen considerably in the recent decade. As the prevalence of sexually transmitted illnesses rises, nations around the world are focusing on developing nationwide screening programs to increase the adoption of sexually transmitted disease diagnostics coverage. Reimbursement regulations for diagnostic services for sexually transmitted diseases have been useful. These factors are significantly contributing to the growth of the global sexually transmitted diseases diagnostics market.

Impact of COVID-19 on Global Sexually Transmitted Disease Testing Market

COVID-19 adversely affected the STD (sexually transmitted disease) testing market. Due to disruptions in healthcare and STD testing facilities, the CDC (Centers for Disease Control and Prevention) observed a decline in STD testing during the early months of COVID-19. Few members may have unwittingly disseminated the virus due to inadequate testing and diagnosis. As a result, even though the transmission of STDs rose during the pandemic, the market value declined due to the decrease in testing. STD testing surged once the lockdown and travel ban were lifted, and the market is projected to boost the expansion of market growth.

Global Sexually Transmitted Disease Testing Market - By Location

Based on location, global sexually transmitted disease testing market is bifurcated in Laboratory and Point of Care (PoC). In 2022, the laboratory testing segment had a higher market share, but PoC testing is expected to rise at a faster rate in the years ahead. Laboratory testing includes commercial/private labs and public health labs. Laboratory testing is a time-consuming but more exact procedure that involves commercial/private labs as well as public health labs. Likewise, the PoC segment includes testing kits, is faster, the results may be less exact. However, bedside testing or mobile testing that allows for rapid healthcare provision for patients is capturing market share. There has been a major transition from traditional laboratory tests to rapid and easy point of care tests, due to the benefits provided by point of care testing equipment.

Competitive Landscape:

Major players operating in global sexually transmitted disease testing market include: Abbott Laboratories, BioMerieux, Inc., Becton Dickinson Company, Danaher Corporation, Bio-Rad Laboratories, Inc., Hologic, Inc., Diasorin Molecular LLC, Roche Holding AG, Orasure Technologies, Inc., Thermo Fisher Scientific Inc., AccuBioTech Co. Ltd., AdvaCare Pharma, BIOGENIX Inc. Pvt. Ltd., CTK Biotech Inc., Everlywell Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, and Merck and Co. Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Sexually Transmitted Disease Testing Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Sexually Transmitted Disease Testing Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Sexually Transmitted Disease Testing Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. High Prevalence & Rise in Incidences of STD across the Globe
      • 3.2.1.2. Implementation of National Screening Programs
      • 3.2.1.3. Supporting Reimbursement of STDs Testing
    • 3.2.2. Restraints
      • 3.2.2.1. Social Stigma Associated with Patients Visiting Specialized STD Clinics
      • 3.2.2.2. Huge Protection of Patients Infected with STDs in Remotes Areas
    • 3.2.3. Opportunities
      • 3.2.3.1. Decrease In Number of Visits to Government Clinics
      • 3.2.3.2. National Screening Programs Across the Globe
      • 3.2.3.3. Niche Opportunities for Technology and POC Test Providers in an Emerging Economy
    • 3.2.4. Challenges
      • 3.2.4.1. Stringent Regulations
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Sexually Transmitted Disease Testing Market Overview

  • 4.1. Market Size & Forecast by Value, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Disease
      • 4.2.1.1. Chlamydia
      • 4.2.1.2. Syphilis
      • 4.2.1.3. Gonorrhoea
      • 4.2.1.4. Hyper Simplex Virus
      • 4.2.1.5. Human Immunodeficiency Virus
      • 4.2.1.6. Chancroid
      • 4.2.1.7. Others
    • 4.2.2. By Location
      • 4.2.2.1. Laboratory
      • 4.2.2.1.1. Commercial/Private Labs
      • 4.2.2.1.2. Public Health Labs
      • 4.2.2.2. Point of Care (POC)
    • 4.2.3. By Device
      • 4.2.3.1. Laboratory Devices
      • 4.2.3.1.1. Thermal Cyclers PCR
      • 4.2.3.1.2. Lateral Flow Readers- Immune Chromatographic Arrays
      • 4.2.3.1.3. Flow Cytometers
      • 4.2.3.1.4. Differential Light Scattering Machines
      • 4.2.3.1.5. Absorbance Micro Plate Reader- Enzyme- Linked Immunosorbent Assay (ELISA)
      • 4.2.3.1.6. Others
      • 4.2.3.2. Point of Care (POC) Devices
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia Pacific
      • 4.2.4.4. Latin America
      • 4.2.4.5. Middle East and Africa

5. North America Sexually Transmitted Disease Testing Market

  • 5.1. Market Size & Forecast by Value, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease
    • 5.2.2. By Location
    • 5.2.3. By Device
    • 5.2.4. By Country
      • 5.2.4.1. US
      • 5.2.4.1.1. By Disease
      • 5.2.4.1.2. By Location
      • 5.2.4.1.3. By Device
      • 5.2.4.2. Canada
      • 5.2.4.2.1. By Disease
      • 5.2.4.2.2. By Location
      • 5.2.4.2.3. By Device

6. Europe Sexually Transmitted Disease Testing Market

  • 6.1. Market Size & Forecast by Value, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease
    • 6.2.2. By Location
    • 6.2.3. By Device
    • 6.2.4. By Country
      • 6.2.4.1. Germany
      • 6.2.4.1.1. By Disease
      • 6.2.4.1.2. By Location
      • 6.2.4.1.3. By Device
      • 6.2.4.2. UK
      • 6.2.4.2.1. By Disease
      • 6.2.4.2.2. By Location
      • 6.2.4.2.3. By Device
      • 6.2.4.3. Italy
      • 6.2.4.3.1. By Disease
      • 6.2.4.3.2. By Location
      • 6.2.4.3.3. By Device
      • 6.2.4.4. France
      • 6.2.4.4.1. By Disease
      • 6.2.4.4.2. By Location
      • 6.2.4.4.3. By Device
      • 6.2.4.5. Spain
      • 6.2.4.5.1. By Disease
      • 6.2.4.5.2. By Location
      • 6.2.4.5.3. By Device
      • 6.2.4.6. The Netherlands
      • 6.2.4.6.1. By Disease
      • 6.2.4.6.2. By Location
      • 6.2.4.6.3. By Device
      • 6.2.4.7. Rest of Europe
      • 6.2.4.7.1. By Disease
      • 6.2.4.7.2. By Location
      • 6.2.4.7.3. By Device

7. Asia-Pacific Sexually Transmitted Disease Testing Market

  • 7.1. Market Size & Forecast by Value, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease
    • 7.2.2. By Location
    • 7.2.3. By Device
    • 7.2.4. By Country
      • 7.2.4.1. China
      • 7.2.4.1.1. By Disease
      • 7.2.4.1.2. By Location
      • 7.2.4.1.3. By Device
      • 7.2.4.2. India
      • 7.2.4.2.1. By Disease
      • 7.2.4.2.2. By Location
      • 7.2.4.2.3. By Device
      • 7.2.4.3. Japan
      • 7.2.4.3.1. By Disease
      • 7.2.4.3.2. By Location
      • 7.2.4.3.3. By Device
      • 7.2.4.4. South Korea
      • 7.2.4.4.1. By Disease
      • 7.2.4.4.2. By Location
      • 7.2.4.4.3. By Device
      • 7.2.4.5. Australia & New Zealand
      • 7.2.4.5.1. By Disease
      • 7.2.4.5.2. By Location
      • 7.2.4.5.3. By Device
      • 7.2.4.6. Indonesia
      • 7.2.4.6.1. By Disease
      • 7.2.4.6.2. By Location
      • 7.2.4.6.3. By Device
      • 7.2.4.7. Malaysia
      • 7.2.4.7.1. By Disease
      • 7.2.4.7.2. By Location
      • 7.2.4.7.3. By Device
      • 7.2.4.8. Singapore
      • 7.2.4.8.1. By Disease
      • 7.2.4.8.2. By Location
      • 7.2.4.8.3. By Device
      • 7.2.4.9. Philippines
      • 7.2.4.9.1. By Disease
      • 7.2.4.9.2. By Location
      • 7.2.4.9.3. By Device
      • 7.2.4.10. Vietnam
      • 7.2.4.10.1. By Disease
      • 7.2.4.10.2. By Location
      • 7.2.4.10.3. By Device
      • 7.2.4.11. Rest of APAC
      • 7.2.4.11.1. By Disease
      • 7.2.4.11.2. By Location
      • 7.2.4.11.3. By Device

8. Latin America Sexually Transmitted Disease Testing Market

  • 8.1. Market Size & Forecast by Value, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease
    • 8.2.2. By Location
    • 8.2.3. By Device
    • 8.2.4. By Country
      • 8.2.4.1. Brazil
      • 8.2.4.1.1. By Disease
      • 8.2.4.1.2. By Location
      • 8.2.4.1.3. By Device
      • 8.2.4.2. Mexico
      • 8.2.4.2.1. By Disease
      • 8.2.4.2.2. By Location
      • 8.2.4.2.3. By Device
      • 8.2.4.3. Argentina
      • 8.2.4.3.1. By Disease
      • 8.2.4.3.2. By Location
      • 8.2.4.3.3. By Device
      • 8.2.4.4. Peru
      • 8.2.4.4.1. By Disease
      • 8.2.4.4.2. By Location
      • 8.2.4.4.3. By Device
      • 8.2.4.5. Colombia
      • 8.2.4.5.1. By Disease
      • 8.2.4.5.2. By Location
      • 8.2.4.5.3. By Device
      • 8.2.4.6. Rest of LATAM
      • 8.2.4.6.1. By Disease
      • 8.2.4.6.2. By Location
      • 8.2.4.6.3. By Device

9. Middle East & Africa Sexually Transmitted Disease Testing Market

  • 9.1. Market Size & Forecast by Value, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease
    • 9.2.2. By Location
    • 9.2.3. By Device
    • 9.2.4. By Country
      • 9.2.4.1. Saudi Arabia
      • 9.2.4.1.1. By Disease
      • 9.2.4.1.2. By Location
      • 9.2.4.1.3. By Device
      • 9.2.4.2. UAE
      • 9.2.4.2.1. By Disease
      • 9.2.4.2.2. By Location
      • 9.2.4.2.3. By Device
      • 9.2.4.3. Qatar
      • 9.2.4.3.1. By Disease
      • 9.2.4.3.2. By Location
      • 9.2.4.3.3. By Device
      • 9.2.4.4. Kuwait
      • 9.2.4.4.1. By Disease
      • 9.2.4.4.2. By Location
      • 9.2.4.4.3. By Device
      • 9.2.4.5. South Africa
      • 9.2.4.5.1. By Disease
      • 9.2.4.5.2. By Location
      • 9.2.4.5.3. By Device
      • 9.2.4.6. Nigeria
      • 9.2.4.6.1. By Disease
      • 9.2.4.6.2. By Location
      • 9.2.4.6.3. By Device
      • 9.2.4.7. Algeria
      • 9.2.4.7.1. By Disease
      • 9.2.4.7.2. By Location
      • 9.2.4.7.3. By Device
      • 9.2.4.8. Rest of MEA
      • 9.2.4.8.1. By Disease
      • 9.2.4.8.2. By Location
      • 9.2.4.8.3. By Device

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Sexually Transmitted Disease Testing Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Sexually Transmitted Disease Testing Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 12.1. Abbott Laboratories
  • 12.2. BioMerieux, Inc.
  • 12.3. Becton Dickinson Company
  • 12.4. Danaher Corporation
  • 12.5. Bio-Rad Laboratories, Inc.
  • 12.6. Hologic, Inc.
  • 12.7. Diasorin Molecular LLC
  • 12.8. Roche Holding AG
  • 12.9. Orasure Technologies, Inc.,
  • 12.10. Thermo Fisher Scientific Inc.
  • 12.11. AccuBioTech Co. Ltd.
  • 12.12. AdvaCare Pharma
  • 12.13. BIOGENIX Inc. Pvt. Ltd.
  • 12.14. CTK Biotech Inc.
  • 12.15. Everlywell Inc.
  • 12.16. F. Hoffmann La Roche Ltd.
  • 12.17. Gilead Sciences Inc.
  • 12.18. GlaxoSmithKline Plc
  • 12.19. Merck and Co. Inc.
  • 12.20. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumption & Limitation